Target intelligence / Profile preview

Acyl-CoA synthetase long-chain family member 6 (ACSL6)

Target
ACSL6
Molecular classification
Enzyme
01

Overview

Acyl-CoA synthetase long-chain family member 6 (ACSL6) is an **enzyme** that catalyzes the conversion of long-chain fatty acids into acyl-CoA derivatives, a key step enabling their use in lipid synthesis, energy production, and cell signaling[1][4]. ACSL6 is vital for the regulation of lipid partitioning, especially in the brain, skeletal muscle, liver, and retina, directing fatty acids toward either storage or oxidation[1][5][6]. Its activity is implicated in metabolic diseases—linked to triglyceride accumulation, insulin resistance, obesity, fatty liver, and cardiovascular disease—and is involved in the regulation of membrane phospholipids critical to neuronal and visual function[2][5][6]. ACSL6 also participates in gene translocation events in certain leukemias[4]. Loss of ACSL6 function in the retina causes photoreceptor degeneration and impaired vision, highlighting its specialized physiological roles[6].

Other names
Long-chain-fatty-acid--CoA ligase 6ACS2FACL6KIAA0837LACS5LACS6LACS2Arachidonate--CoA ligasefatty-acid-Coenzyme A ligaselong-chain 6long-chain acyl-CoA synthetase 6
02

Mechanism of action

Enzymes such as ACSL6 are targeted experimentally to modulate lipid metabolism, fatty acid uptake, and storage; inhibition or knockdown leads to altered lipid partitioning and mitochondrial function[5].

03

Biological functions

Fatty acid activationFatty acid metabolismLipid synthesis/storageBeta-oxidationCell signalingEnergy production
04

Disease associations

Metabolic syndromeNon-alcoholic fatty liver diseaseObesityCardiovascular diseaseLeukemia (in the context of gene translocation)Myelodysplastic syndromeRetinal neurodegenerationOther metabolic diseases
05

Safety considerations

Potential metabolic disturbances (hepatic steatosis, insulin resistance) from altered ACSL6 activityRisks of lipid accumulation or deficiency in essential fatty acidsNeurodegeneration and visual dysfunction from disruption of ACSL6-regulated lipid metabolism in brain and retina[6]
06

Biomarkers

Elevated ACSL6 expression (biomarker for metabolic syndrome, NAFLD, cardiovascular risk)[2]gene translocation with ETV6 (biomarker in some leukemias)[4]

Beyond the preview

Go deeper on Acyl-CoA synthetase long-chain family member 6 (ACSL6).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acyl-CoA synthetase long-chain family member 6 (ACSL6).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call